J. Wanders - Concepedia

Author

J. Wanders

The Netherlands Cancer Institute

Also Known As

J A W Wanders, J Wanders, J. Wanders, Jantien Wanders

144

Publications

23.5K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Eisai (United Kingdom)Slotervaartziekenhuis European Organisation for Research and Treatment of Cancer Utrecht University

About

J. Wanders is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	71	21.3K
2	Health Sciences	9	9	17.5K
3	Biochemistry	2	2	23
4	Natural Sciences	1	1	10
5	Public Health	1	1	39

J. Wanders

Publications

23.3K

Citations

H-Index

Page 1

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Javier Cortés, Joyce O’Shaughnessy, David Loesch, The Lancet Metastatic Breast CancerOncologyBreast OncologyCancer ManagementClinical Trials	2011	1.1K
New guidelines to evaluate the response to treatment in solid tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Breast Cancer Solid TumorsMedicineCancer ManagementNew GuidelinesCancer Treatment	2005	662
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Andrea Ardizzoni, H. Hansen, P Dombernowsky, Journal of Clinical Oncology	1997	479
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin M. Borner, Patrick Schöffski, Ronald de Wit, European Journal of Cancer Intravenous FluorouracilPharmacologyPatient PreferencePharmacotherapyMedicine	2002	314
Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck G. Catimel, Jaap Verweij, Vera Mattijssen, Annals of Oncology Active DrugMedicinePharmacotherapyHead And Neck CancerDermatology	1994	258
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, The Lancet Oncology Soft-tissue SarcomaPathologyPhase 2Radiation OncologyEribulin Mesylate	2011	236
Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group Aarón Sulkes, Joan A. Smyth, C. Sessa, British Journal of Cancer Gastrointestinal OncologyAdvanced Gastric CancerMedicineCancer ManagementGastroenterology	1994	220
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine Javier Cortés, Linda T. Vahdat, Joanne L. Blum, Journal of Clinical Oncology	2010	215
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Andreas M. Kaufmann, Peter L. Stern, Elaine M. Rankin, PubMed	2002	204

Page 1